CoChat

Reducing protein oxidation reverses lung fibrosis

Open access
Anathy, Vikas, Lahue, Karolyn G., Chapman, David G., Chia, Shi B., Casey, Dylan T., Aboushousha, Reem, van der Velden, Jos L. J., Elko, Evan, Hoffman, Sidra M., McMillan, David H., Jones, Jane T., Nolin, James D., Abdalla, Sarah, Schneider, Robert, Seward, David J., Roberson, Elle C., Liptak, Matthew D., Cousins, Morgan E., Butnor, Kelly J., Taatjes, Douglas. J., Budd, Ralph C., Irvin, Charles G., Ho, Ye-Shih, Hakem, Razq, Brown, Kevin K., Matsui, Reiko, Bachschmid, Markus M., Gomez, Jose L., Kaminski, Naftali, van der Vliet, Albert, Janssen-Heininger, Yvonne M. W. · 2018 · Nature Medicine
Cited by 120

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Idiopathic pulmonary fibrosis is characterized by excessive deposition of collagen in the lung, leading to chronically impaired gas exchange and death1–3. Oxidative stress is believed to be critical in this disease pathogenesis4–6, although the exact mechanisms remain enigmatic. Protein S-glutathionylation (PSSG) is a post-translational modification of proteins that can be reversed by glutaredoxin-1 (GLRX)7. It remains unknown whether GLRX and PSSG play a role in lung fibrosis. Here, we explored the impact of GLRX and PSSG status on the pathogenesis of pulmonary fibrosis, using lung tissues from subjects with idiopathic pulmonary fibrosis, transgenic mouse models and direct administration of recombinant Glrx to airways of mice with existing fibrosis. We demonstrate that GLRX enzymatic activity was strongly decreased in fibrotic lungs, in accordance with increases in PSSG. Mice lacking Glrx were far more susceptible to bleomycin- or adenovirus encoding active transforming growth factor beta-1 (AdTGFB1)-induced pulmonary fibrosis, whereas transgenic overexpression of Glrx in the lung epithelium attenuated fibrosis. We furthermore show that endogenous GLRX was inactivated through an oxidative mechanism and that direct administration of the Glrx protein into airways augmented Glrx activity and reversed increases in collagen in mice with TGFB1- or bleomycin-induced fibrosis, even when administered to fibrotic, aged animals. Collectively, these findings suggest the therapeutic potential of exogenous GLRX in treating lung fibrosis. Targeting a post-translational modification of Fas by recombinant Glrx reverses established lung fibrosis in a mouse model of age-related idiopathic pulmonary fibrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-018-0090-y

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 120

Metadata

Authors
Anathy, V., Lahue, K. G., Chapman, D. G., Chia, S. B., Casey, D. T., Aboushousha, R., van der Velden, J. L. J., Elko, E., Hoffman, S. M., McMillan, D. H., Jones, J. T., Nolin, J. D., Abdalla, S., Schneider, R., Seward, D. J., Roberson, E. C., Liptak, M. D., Cousins, M. E., Butnor, K. J., Taatjes, D. J., Budd, R. C., Irvin, C. G., Ho, Y.-S., Hakem, R., Brown, K. K., Matsui, R., Bachschmid, M. M., Gomez, J. L., Kaminski, N., van der Vliet, A., & Janssen-Heininger, Y. M. W.
Venue
Nature Medicine
Published
2018-07-09
Volume
24
Issue
8
Pages
1128-1135
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2871400816
Cited by
120
References
12
FWCI
8.12
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reducing protein oxidation reverses lung fibrosis. https://app.cochat.ai/papers/10.1038/s41591-018-0090-y
The paper
Anathy, V., Lahue, K. G., Chapman, D. G., Chia, S. B., Casey, D. T., Aboushousha, R., van der Velden, J. L. J., Elko, E., Hoffman, S. M., McMillan, D. H., Jones, J. T., Nolin, J. D., Abdalla, S., Schneider, R., Seward, D. J., Roberson, E. C., Liptak, M. D., Cousins, M. E., Butnor, K. J., . . . Janssen-Heininger, Y. M. W. (2018). Reducing protein oxidation reverses lung fibrosis. Nature Medicine. https://doi.org/10.1038/s41591-018-0090-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.